ARVACthe first Argentine vaccine once morest Covid, entered the last stretch of clinical trials, the main people responsible for its development announced: the National University of San Martín, the Conicet and the Pablo Cassará Laboratory.
Designed since May 2020 as protection once morest variants circulating in the region, including a bivalent version for omicronalready proved to be safe during the initial phase of the investigation, with values of “promising” immune response.
For the WHO, all the theories regarding the origin of COVID-19 are still on the table
This new stage -in charge of the same team that tested the Pfizer vaccine in Argentina- will evaluate the performance of three formulas in 1,782 volunteers, distributed in 10 centers in four provinces and the city of Buenos Aires. The call, which is still open on the arvac.com.ar site, is for adults who have received up to three doses of vaccines once morest the disease and reside in CABA, La Plata, Mar del Plata, Córdoba capital, Mendoza capital or Salta capital. After this phase, the results will be presented to the ANMAT for approval as reinforcement.
ARVAC is named following Cecilia Grierson (1859-1934), the first doctor and one of the first fighters for women’s rights in the country, who was also a teacher, governess and pioneer in the fields of obstetrics, kinesiology, childcare and the dissemination of first aid. Grierson he marked all his books with the Latin phrase things, not words: “facts, not words”. A motto that, a century later, the researchers who are regarding to mark another milestone for Argentine science.
JL
You may also like
